Format

Send to

Choose Destination
See comment in PubMed Commons below
Parasite Immunol. 2009 Sep;31(9):574-81. doi: 10.1111/j.1365-3024.2009.01144.x.

Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines.

Author information

1
Fogarty International Center, National Institutes of Health, Bethesda, MD, USA. wendypomeara@gmail.com

Abstract

A recent working group convened by the World Health Organization recommended that time to first or only episode of clinical malaria should be used to evaluate vaccine efficacy in phase III trials. However, calculating vaccine efficacy based on this endpoint misses important aspects of malaria disease and transmission. Here, we discuss the gaps that this approach leaves in predicting the potential public health impact of a vaccine and the challenges faced by vaccine trial designers. We examine the implications of current vaccine trial design on effectiveness studies and the next generation of malaria vaccines.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center